Is anyone interested? Chinese ipo didn\'t do very well lately, is there any good potential for SCR?
Simcere Pharmaceutical, a manufacturer of branded generic pharmaceuticals in China, priced its IPO Thursday evening. The offering consists of 15.6 million ADSs, including 3.1 million from selling shareholders, at a price of $14.50 per ADS, the top of the proposed $12.50 to $14.50 range. Each ADS will represent two ordinary shares. The ADSs are expected to begin trading on the NYSE under the ticker SCR Friday. Goldman Sachs was the bookrunner on the deal.
http://www.simcere.com/index.asp